FLGT
Fulgent Genetics, Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | -$15.2M | Q1 2026 | — |
|
|
|||
| Shares repurchased | 2.6M | Q1 2026 | — |
| Cash, cash equivalents, restricted cash, and investments in marketable securities | $705.5M | Full Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FLGT
this stock
Fulgent Genetics, Inc.
|
$583.63M | -20.0% | +2.5% | — | 9.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$199.75B | -7.5% | +0.4% | 29.6 | 1.4% |
|
DHR
Danaher Corp /De/
|
$145.10B | -11.9% | +8.5% | 39.6 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$45.55B | -17.7% | +10.4% | 42.5 | 2.5% |
|
NTRA
Natera, Inc.
|
$38.64B | +17.8% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FLGT | +1.9% | +14.5% | -24.6% | +2.4% | -20.0% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | +0.7% | +14.7% | -34.7% | +1.3% | -30.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.